ETERNAL - Boosting the reduction of the environmental impact of pharmaceutical products throughout their entire life cycle

ETERNAL - 促进减少药品在其整个生命周期中对环境的影响

• 批准号: 10038763
• 金额: $ 58.03万
• 依托单位: QUOTIENT SCIENCES (ALNWICK) LIMITED
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10038763
• 关键词: ETERNAL; Boosting; reduction; environmental; impact

ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promotingfull life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only the APIand residues/metabolites, but other chemicals and by-products of the production process. This type of approach is essential to take intoconsideration the types of green manufacturing approach under consideration by the pharmaceutical industry, as evidenced by the rangeand scope of case studies being undertaken within ETERNAL. Specific application of our risk and life cycle assessment approachesto the ETERNAL case studies is a key element of the proposed work and will provide industry and policymakers with key examplesof how whole life cycle assessment may be used to evaluate the changes in environmental impacts expected due to the introduction ofgreen manufacturing processes.

ETERNAL旨在通过使用和推广涵盖设计、制造、使用和处置的全生命周期方法，不仅评估原料药和残留物/代谢物的环境风险，还评估生产过程中其他化学品和副产品的环境风险，为药品制造、使用和处置的可持续发展做出贡献。这种类型的方法对于考虑制药行业正在考虑的绿色制造方法类型至关重要，ETERNAL内正在进行的案例研究的范围和范围就证明了这一点。具体应用我们的风险和生命周期评估方法的ETERNAL案例研究是一个关键因素的拟议工作，并将提供行业和政策制定者的关键exampleshow全生命周期评估可用于评估的变化，预计由于引入绿色制造工艺的环境影响。